-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On February 28, another batch of pharmaceutical companies in the A-share and two cities released their 2021 annual performance reports, including at least 7 companies including Kexing Pharmaceuticals, Techsun Medical, Nanxin Pharmaceuticals, Rejing Bio, Haohai Biotechnology, and Xinhecheng.
.
Among them, 5 reported good news, 1 net profit declined, and another turned from profit to loss
.
Kexing Pharmaceuticals: Net profit fell by 35.
16% year-on-year.
In 2021, Kexing Pharmaceuticals achieved operating income of about 1.
285 billion yuan, a year-on-year increase of 5.
31%; realized attributable net profit of about 90.
2106 million yuan, a year-on-year decrease of 35.
16%
.
Regarding the decline in performance, the company stated that it was mainly because the company increased investment in research and development and actively carried out research and development activities during the reporting period, and the research and development expenses increased significantly compared with the same period of last year; in order to help the company's high-quality development to introduce excellent management and technical talents, the labor cost increased year-on-year; the reporting period The company consolidated product sales channels, implemented refined management and wide coverage of terminals, and increased sales expenses
.
Tesson Medical: Net profit increased by 24.
20% year-on-year In 2021, Tesson Medical achieved operating income of 214 million yuan, a year-on-year increase of 31.
01%; net profit attributable to owners of the parent company was 43.
4049 million yuan, a year-on-year increase of 24.
20%
.
The company stated that in 2021, the company will overcome the impact of the epidemic, continue to increase investment in research and development, promote technological innovation and product iteration, actively respond to market changes and continue to expand, expand sales, continue to optimize cost control, and maintain high growth on the premise of ensuring profitability.
, to achieve high-quality development
.
Nanxin Pharmaceutical: From profit to loss Nanxin Pharmaceutical achieved operating income of 688 million yuan from January to December 2021, down 36.
81% from the same period of the previous year; net profit attributable to shareholders of the parent company was -176 million yuan, compared with the previous year.
Turned from profit to loss in the same period
.
It is understood that in 2021, the sales revenue of the company's core product "Liwei" affected by the epidemic will decrease by more than 50% compared with the same period in 2020
.
"Xinke" (simvastatin dispersible tablets) is affected by the national generic drug consistency evaluation policy, and the sales revenue in 2021 will decrease by 62.
57% compared with the same period in 2020
.
In addition, "Cefaclor Capsules" (Cefaclor Capsules) entered the national centralized procurement catalog of pharmaceutical products at the end of 2020, and the sales revenue in 2021 decreased by 67.
67% compared with the same period in 2020
.
Rejing Bio: Net profit increased by 1856.
81% year-on-year.
In 2021, Rejing Bio achieved operating income of 5.
372 billion yuan, a year-on-year increase of 946.
14%; net profit attributable to the parent was 2.
193 billion yuan, a year-on-year increase of 1856.
81%
.
The announcement shows that the main reason for the growth in performance is that the antigen self-test products developed by the company have successively passed the self-test registration/filing in major economies such as Germany and the European Union, and are quickly applied to local anti-epidemic needs as the epidemic continues abroad in 2021.
Foreign trade orders increased significantly
.
Haohai Biotechnology: Net profit increased by 53.
19% year-on-year The total operating income of Haohai Biotechnology in 2021 was 1.
766 billion yuan, an increase of 32.
57% compared with the same period of the previous year; the net profit attributable to shareholders of the parent company was 352 million yuan, a year-on-year increase of 352 million yuan.
The same period increased by 53.
19%
.
The main reasons for the increase in performance include: the increase in operating income of the Group and the increase in gross profit brought about by the relatively stable overall gross profit margin
.
At the same time, with the weakening of the impact of the epidemic, various marketing and marketing activities, administrative management activities, and bonus distribution have gradually returned to normal, resulting in an increase in the Group's operating expenses and management expenses compared with the same period of the previous year
.
Xinhecheng: Net profit increased by 20.
92% year-on-year.
Xinhecheng's total operating income in 2021 will be 14.
781 billion yuan, an increase of 43.
31% over the same period of the previous year; the net profit attributable to shareholders of listed companies is 4.
309 billion yuan, an increase over the same period last year.
20.
92%
.
It is reported that during the reporting period, in the face of the continuous impact of foreign epidemics and changes in the product market, the company actively took countermeasures, seized market opportunities, and maintained a good development trend of production and operation
.
Xiangsheng Medical: Net profit increased by 20.
26% year-on-year.
Xiangsheng Medical’s total operating income from January to December 2021 was 407 million yuan, an increase of 22.
10% over the same period of the previous year; the net profit attributable to shareholders of the parent company was 119 million yuan, a year-on-year increase.
an increase of 20.
26%
.
Regarding the reasons that affect the operating performance, the announcement shows that during the reporting period, the company continued to increase the research and development of new products, made pre-research reserves for medium and long-term new technologies, continued to maintain a high proportion of research and development investment, and the annual research and development expenses increased by 29.
82% year-on-year.
In addition, the company also vigorously developed domestic and foreign markets, accelerated the construction of marketing system and network layout, and the annual sales expenses increased by 31.
11% year-on-year
.
Both research and development expenses and sales expenses have increased significantly, resulting in a slightly lower growth rate of net profit than that of operating income
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Among them, 5 reported good news, 1 net profit declined, and another turned from profit to loss
.
Kexing Pharmaceuticals: Net profit fell by 35.
16% year-on-year.
In 2021, Kexing Pharmaceuticals achieved operating income of about 1.
285 billion yuan, a year-on-year increase of 5.
31%; realized attributable net profit of about 90.
2106 million yuan, a year-on-year decrease of 35.
16%
.
Regarding the decline in performance, the company stated that it was mainly because the company increased investment in research and development and actively carried out research and development activities during the reporting period, and the research and development expenses increased significantly compared with the same period of last year; in order to help the company's high-quality development to introduce excellent management and technical talents, the labor cost increased year-on-year; the reporting period The company consolidated product sales channels, implemented refined management and wide coverage of terminals, and increased sales expenses
.
Tesson Medical: Net profit increased by 24.
20% year-on-year In 2021, Tesson Medical achieved operating income of 214 million yuan, a year-on-year increase of 31.
01%; net profit attributable to owners of the parent company was 43.
4049 million yuan, a year-on-year increase of 24.
20%
.
The company stated that in 2021, the company will overcome the impact of the epidemic, continue to increase investment in research and development, promote technological innovation and product iteration, actively respond to market changes and continue to expand, expand sales, continue to optimize cost control, and maintain high growth on the premise of ensuring profitability.
, to achieve high-quality development
.
Nanxin Pharmaceutical: From profit to loss Nanxin Pharmaceutical achieved operating income of 688 million yuan from January to December 2021, down 36.
81% from the same period of the previous year; net profit attributable to shareholders of the parent company was -176 million yuan, compared with the previous year.
Turned from profit to loss in the same period
.
It is understood that in 2021, the sales revenue of the company's core product "Liwei" affected by the epidemic will decrease by more than 50% compared with the same period in 2020
.
"Xinke" (simvastatin dispersible tablets) is affected by the national generic drug consistency evaluation policy, and the sales revenue in 2021 will decrease by 62.
57% compared with the same period in 2020
.
In addition, "Cefaclor Capsules" (Cefaclor Capsules) entered the national centralized procurement catalog of pharmaceutical products at the end of 2020, and the sales revenue in 2021 decreased by 67.
67% compared with the same period in 2020
.
Rejing Bio: Net profit increased by 1856.
81% year-on-year.
In 2021, Rejing Bio achieved operating income of 5.
372 billion yuan, a year-on-year increase of 946.
14%; net profit attributable to the parent was 2.
193 billion yuan, a year-on-year increase of 1856.
81%
.
The announcement shows that the main reason for the growth in performance is that the antigen self-test products developed by the company have successively passed the self-test registration/filing in major economies such as Germany and the European Union, and are quickly applied to local anti-epidemic needs as the epidemic continues abroad in 2021.
Foreign trade orders increased significantly
.
Haohai Biotechnology: Net profit increased by 53.
19% year-on-year The total operating income of Haohai Biotechnology in 2021 was 1.
766 billion yuan, an increase of 32.
57% compared with the same period of the previous year; the net profit attributable to shareholders of the parent company was 352 million yuan, a year-on-year increase of 352 million yuan.
The same period increased by 53.
19%
.
The main reasons for the increase in performance include: the increase in operating income of the Group and the increase in gross profit brought about by the relatively stable overall gross profit margin
.
At the same time, with the weakening of the impact of the epidemic, various marketing and marketing activities, administrative management activities, and bonus distribution have gradually returned to normal, resulting in an increase in the Group's operating expenses and management expenses compared with the same period of the previous year
.
Xinhecheng: Net profit increased by 20.
92% year-on-year.
Xinhecheng's total operating income in 2021 will be 14.
781 billion yuan, an increase of 43.
31% over the same period of the previous year; the net profit attributable to shareholders of listed companies is 4.
309 billion yuan, an increase over the same period last year.
20.
92%
.
It is reported that during the reporting period, in the face of the continuous impact of foreign epidemics and changes in the product market, the company actively took countermeasures, seized market opportunities, and maintained a good development trend of production and operation
.
Xiangsheng Medical: Net profit increased by 20.
26% year-on-year.
Xiangsheng Medical’s total operating income from January to December 2021 was 407 million yuan, an increase of 22.
10% over the same period of the previous year; the net profit attributable to shareholders of the parent company was 119 million yuan, a year-on-year increase.
an increase of 20.
26%
.
Regarding the reasons that affect the operating performance, the announcement shows that during the reporting period, the company continued to increase the research and development of new products, made pre-research reserves for medium and long-term new technologies, continued to maintain a high proportion of research and development investment, and the annual research and development expenses increased by 29.
82% year-on-year.
In addition, the company also vigorously developed domestic and foreign markets, accelerated the construction of marketing system and network layout, and the annual sales expenses increased by 31.
11% year-on-year
.
Both research and development expenses and sales expenses have increased significantly, resulting in a slightly lower growth rate of net profit than that of operating income
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
